# SJMB12

Source: https://onco.cc/trials/sjmb12/  
OnCo record `sjmb12` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SJMB12 is the St. Jude trial that first treated medulloblastoma by its molecular type: children with the low-risk WNT form receive a much lower dose of radiotherapy to the brain and spine, those with the SHH form add the targeted drug vismodegib, and the others add two extra chemotherapy drugs; it is still running and the corpus records the design.

## Summary

SJMB12 is a non-randomised phase 2 trial at St. Jude Children's Research Hospital and partner centres in which newly diagnosed medulloblastoma is assigned to strata by molecular subgroup (WNT, SHH, group 3 and 4) and clinical risk. Low-risk WNT patients receive craniospinal irradiation of 15 Gy with a reduced boost and four cycles of cyclophosphamide, cisplatin and vincristine; skeletally mature SHH patients add maintenance vismodegib; intermediate- and high-risk non-WNT, non-SHH patients add pemetrexed and gemcitabine. Randomised sub-studies test aerobic training and cognitive remediation. The primary endpoints are progression-free survival at two years in the low-risk WNT, standard-risk SHH and standard-risk group 3 and 4 strata.

The registry lists 660 participants with a primary completion date of October 2028 and no posted results. The corpus's WNT medulloblastoma page cites SJMB12 for 15 Gy craniospinal radiotherapy alongside the COG ACNS1422 study of 18 Gy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: St. Jude SJMB12
- Tags: soc-trials
- Registry id: NCT01878617
- Phase: 2
- Setting: Newly diagnosed medulloblastoma aged 3 to 39, stratified by molecular subgroup and clinical risk: reduced craniospinal irradiation (15 Gy) for low-risk WNT tumours, vismodegib added for skeletally mature SHH tumours, and pemetrexed and gemcitabine added for intermediate- and high-risk group 3 and 4 tumours, with exercise and cognitive remediation randomisations
- Sponsor: St. Jude Children's Research Hospital
- Enrolled: 660

## Sources

- ClinicalTrials.gov NCT01878617: https://clinicaltrials.gov/study/NCT01878617

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/), [Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)](https://onco.cc/cancers/medulloblastoma-group-3-4/), [Medulloblastoma](https://onco.cc/cancers/medulloblastoma/), [SHH-activated medulloblastoma](https://onco.cc/cancers/medulloblastoma-shh/), [WNT-activated medulloblastoma](https://onco.cc/cancers/medulloblastoma-wnt/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Proton therapy](https://onco.cc/technologies/proton-therapy/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Vincristine](https://onco.cc/drugs/vincristine/), [Vismodegib](https://onco.cc/drugs/vismodegib/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- institutions: [St. Jude Children's Research Hospital](https://onco.cc/institutions/st-jude/)

---
JSON: https://onco.cc/api/v1/entities/sjmb12.json